Malignant Uterine Corpus Neoplasm
NCI Definition: A malignant neoplasm that affects the uterine corpus. Representative examples include endometrial carcinoma, carcinosarcoma, leiomyosarcoma, and adenosarcoma. 
Malignant uterine corpus neoplasms most frequently harbor alterations in TP53, PTEN, PIK3CA, ARID1A, and PIK3R1 .
PIK3CA Mutation, TP53 Mutation, PTEN Mutation, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in malignant uterine corpus neoplasm .
There are 3 clinical trials for malignant uterine corpus neoplasm, of which 2 are open and 1 is completed or closed. Of the trials that contain malignant uterine corpus neoplasm as an inclusion criterion, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open).
Gnx102, ng-350a, and anlotinib are the most common interventions in malignant uterine corpus neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.